# A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct04632108/  
OnCo record `nct04632108` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ASKB589 Injection in advanced solid tumours, run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active and no longer recruiting.

## Summary

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04632108 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 199 participants enrolled, started 2021-01-28 and due to reach its primary completion in 2025-10-31. Interventions recorded: ASKB589 Injection.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04632108
- Phase: 1/2
- Setting: A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Enrolled: 199

## Sources

- ClinicalTrials.gov NCT04632108: https://clinicaltrials.gov/study/NCT04632108

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04632108.json